Clinical Trials Sponsored by Cadila Pharnmaceuticals

Total 19672 results

Cadila Pharnmaceuticals

Completed

A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

India
Cadila Pharnmaceuticals

Completed

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder (STCC)

Bladder Cancer

India
Cadila Pharnmaceuticals

Terminated

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer (HRPC)

Hormone Refractory Prostate Cancer

India
Cadila Pharnmaceuticals

Terminated

Safety Study of CADI-05 in Patients With Advanced Stage Melanoma

Stage III or Stage IV Melanoma

United States
Cadila Pharnmaceuticals

Completed

Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder (STCC)

Bladder Cancer

India
Cadila Pharnmaceuticals

Completed

Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure

Anemia

India
ACADIA Pharmaceuticals Inc.

Not yet recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Alzheimer's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Schizophrenia

Lithuania, Canada, Ukraine, Argentina, Bulgaria, Croatia, Czechia, Hungary, Italy, Poland, Russian Federation, Serbia, Spain, United States
ACADIA Pharmaceuticals Inc.

Completed

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome (DAFFODIL™)

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Terminated

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Ukraine, United Kingdom, Slovakia, South Africa
ACADIA Pharmaceuticals Inc.

Completed

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

Parkinson's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Completed

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Treatment of Depression in Adults With Parkinson's Disease (PD)

United States
ACADIA Pharmaceuticals Inc.

Completed

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

Schizophrenia

United States, Russian Federation, Hungary, Bulgaria, Serbia, Ukraine, Lithuania, Canada, Czechia, Poland
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

United States, Austria, France, Canada, Belgium, Russian Federation, Serbia, Ukraine, Poland, Portugal, Italy, India, United Kingdom, Sweden
ACADIA Pharmaceuticals Inc.

Completed

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Schizophrenia

United States, Brazil
ACADIA Pharmaceuticals Inc.

Completed

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Parkinson's Disease | Hallucinations | Psychoses

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Hyperphagia in Prader-Willi Syndrome

United States, Canada
ACADIA Pharmaceuticals Inc.

Recruiting

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

Irritability Associated With Autism Spectrum Disorder

United States, Spain, France, Australia, Poland, Italy, Hungary
ACADIA Pharmaceuticals Inc.

Completed

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LILAC™)

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Active, not recruiting

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2)

Schizophrenia

Argentina, Bulgaria, Croatia, Czechia, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Ukraine
ACADIA Pharmaceuticals Inc.

Completed

Open-Label Extension Study of Trofinetide for Rett Syndrome

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Completed

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Completed

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

United States, Russian Federation, Serbia, Poland, Georgia, Czechia, Bulgaria, Colombia, Mexico, Romania, South Africa, Ukraine
ACADIA Pharmaceuticals Inc.

Terminated

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Parkinson's Disease

United States
ACADIA Pharmaceuticals Inc.

Terminated

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Parkinson Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Completed

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Dementia-related Psychosis

United States, Spain, Poland, Ukraine, Chile, Czechia, United Kingdom, Bulgaria, France, Germany, Italy, Serbia, Slovakia
ACADIA Pharmaceuticals Inc.

Completed

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

Schizophrenia

United States, Spain, Hungary, Bulgaria, Russian Federation, Serbia, Ukraine, Poland, Canada, Czechia
ACADIA Pharmaceuticals Inc.

Completed

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

Agitation and Aggression in Alzheimer's Disease

United States, Spain, Chile, France, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Adjunctive Treatment of Major Depressive Disorder

United States
ACADIA Pharmaceuticals Inc.

Terminated

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

Agitation and Aggression in Alzheimer's Disease

United States, France, Spain, Chile, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

France, United States, Bulgaria, Russian Federation, United Kingdom, Ukraine, India
ACADIA Pharmaceuticals Inc.

Completed

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Schizophrenia

United States
Adial Pharmaceuticals

Completed

Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms (ONWARD)

Alcohol Use Disorder

Bulgaria, Croatia, Estonia, Finland, Latvia, Poland, Sweden
ACADIA Pharmaceuticals Inc.

Recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Irritability Associated With Autism Spectrum Disorder

United States, Spain, France, Hungary, Poland, Italy
ACADIA Pharmaceuticals Inc.

Completed

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Completed

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Serbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
ACADIA Pharmaceuticals Inc.

Completed

Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Acute Postoperative Pain | Bunionectomy

United States
ACADIA Pharmaceuticals Inc.

Terminated

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Osteoarthritis Pain

United States
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis

United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Spain, United States, Belgium, Austria, Serbia, Poland, Portugal, Italy, Sweden
ACADIA Pharmaceuticals Inc.

Approved for marketing

Expanded Access of Pimavanserin for Patients With PD Psychosis

Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

United States, Canada
Cadila Pharnmaceuticals
Council of Scientific and Industrial Research, India

Completed

A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients

COVID-19

India
Cadila Pharnmaceuticals
Council of Scientific and Industrial Research, India

Unknown

Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill

COVID-19

India
Cadila Pharnmaceuticals
Council of Scientific and Industrial Research, India

Unknown

Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19

COVID-19

India
Darnitsa Pharmaceutical Company
ACDIMA Biocenter

Completed

Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers

Healthy Subjects | Bioequivalence

Jordan
Darnitsa Pharmaceutical Company
ACDIMA Biocenter

Completed

Bioequivalence Study of Test and Reference 50 mg Eplerenone Film-coated Tablets in Healthy Volunteers

Healthy Subjects | Bioequivalence

Jordan
St. John's Research Institute
Population Health Research Institute; Cadila Pharnmaceuticals

Completed

The Indian POLYCAP Study (TIPS)

Cardiovascular Diseases

India

Clinical Trials Sponsored by Cadila Pharnmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations